"A startup company, Ambrosia, has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a clinical trial ... The clinical tri

"A startup company, Ambrosia, has been selling "young blood transfusions" for $8,000 since 2017 under the guise of running a clinical trial ... The clinical trial has no control arm and so is neither randomized nor blind. The company was started by Jesse Karmazin, a medical school graduate without a license to practice medicine. David Wright is the licensed doctor overseeing the clinical trial; in his practice he administers intravenous treatments of vitamins and antibiotics for nontraditional purposes and was disciplined by the California Medical Board for the latter in 2015. Jonathan Kimmelman, a bioethicist from McGill University, suggests that Ambrosia is running this trial as they would be unable to get FDA approval to sell this treatment otherwise." [1] [1] https://en.wikipedia.org/wiki/Young_blood_transfusion#Ambrosia https://en.wikipedia.org/wiki/Young_blood_transfusion#Ambros...